Fujian Aonong Biological Technology Group Incorporation (603363) Fundamentals 2026 — P/E 67.8x, Revenue Analysis | SniperIQ
Fujian Aonong Biological Technology Group Incorporation (603363) is a CN-listed Consumer Defensive company in Agricultural Farm Products with a market capitalization of ¥7.5B, trading at ¥2.74 on the SHH. This SniperIQ fundamentals page covers Fujian Aonong Biological Technology Group Incorporation's valuation (P/E 67.8x, P/B 1.2x), profitability (net margin -1.7%), revenue (¥8.5B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Fujian Aonong Biological Technology Group Incorporation's market cap?
Fujian Aonong Biological Technology Group Incorporation (603363) has a market capitalization of approximately ¥7.5B, trading at ¥2.74 on the SHH. Market cap moves with the live share price.
What is Fujian Aonong Biological Technology Group Incorporation's P/E ratio?
Fujian Aonong Biological Technology Group Incorporation's trailing twelve-month P/E ratio is 67.8x, with a price-to-book (P/B) of 1.2x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Fujian Aonong Biological Technology Group Incorporation?
Fujian Aonong Biological Technology Group Incorporation runs a net profit margin of -1.7%, a gross margin of 5.3%, and an operating margin of -2.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Fujian Aonong Biological Technology Group Incorporation generate?
Fujian Aonong Biological Technology Group Incorporation reported revenue of ¥8.5B for fiscal year 2025, with net income of ¥78M and earnings per share (EPS) of 0.03. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Fujian Aonong Biological Technology Group Incorporation pay a dividend?
Fujian Aonong Biological Technology Group Incorporation does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Fujian Aonong Biological Technology Group Incorporation financially healthy?
Fujian Aonong Biological Technology Group Incorporation carries a debt-to-equity ratio of 0.76x and a current ratio of 0.93x, with a market beta of 0.39. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Fujian Aonong Biological Technology Group Incorporation a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Fujian Aonong Biological Technology Group Incorporation (603363) the key facts are: market cap ¥7.5B, P/E 67.8x, revenue ¥8.5B, 52-week range 2.6-6.2. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Fujian Aonong Biological Technology Group Incorporation's full fundamentals live
Get Fujian Aonong Biological Technology Group Incorporation's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.